Opthea Reports Half-Year Financial Results and Business Updates
Opthea Limited - American Depositary Shares (OPT)
Company Research
Source: GlobeNewswire
Enrollment completion of sozinibercept Phase 3 program for wet AMD expected in calendar year (CY) Q2 2024 with top-line data mid-CY 2025 Expanded U.S. leadership team with the appointments of Dr. Frederic Guerard as CEO, Peter Lang as CFO, and Dr. Arshad M. Khanani as Chief Medical Advisor Cash and cash equivalents of $157.1 million as of December 31, 2023 MELBOURNE, Australia and PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT; “Opthea”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, today announced financial results for the six months ended December 31, 2023 and highlighted recent corporate and clinical updates. “It is a transformative time for Opthea. We substantially advanced the development of sozinibercept, our lead product candidate for the treatment of wet age-related macular degeneration (wet AMD), expanded our U.S. leadership team, strengt
Show less
Read more
Impact Snapshot
Event Time:
OPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPT alerts
High impacting Opthea Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
OPT
News
- Opthea to Present at the OIS Retina Innovation Summit at ARVO [Yahoo! Finance]Yahoo! Finance
- Opthea to Present at the OIS Retina Innovation Summit at ARVOGlobeNewswire
- Owning 39% shares,institutional owners seem interested in Opthea Limited (ASX:OPT), [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints John Han, PharmD, as VP Medical Affairs [Yahoo! Finance]Yahoo! Finance
- Opthea Appoints John Han, PharmD, as VP Medical AffairsGlobeNewswire
OPT
Sec Filings
- 4/25/24 - Form 6-K
- 4/9/24 - Form 6-K
- 4/5/24 - Form 6-K
- OPT's page on the SEC website